Table 3.
Cox univariate analysis
| VARIABLES | HR | CI | P value |
|---|---|---|---|
| Age (per 1 year increase) | 0.93 | 0.88–0.99 | 0.0048 |
|
Sex -Cis-gender woman - Cis-gender man - Transgender woman |
0 1.85 5.90 |
0.23–14.8 0.36–96.7 |
0.563 0.213 |
|
Ethnicity -Caucasian - Non Caucsian |
0 1.25 |
0.40-18.32 | 0.90 |
|
Risk Factor n (%) MSM Heterosexual PWID |
0 1.13 0.002 |
0.32-4.00 0.001–1.03 |
0.849 0.982 |
| Zenith HIV-RNA (per 1 log10 copies/mL increased) | 0.74 | 0.40–1.38 | 0.342 |
| Nadir CD4, (per 100 CD4 cell count increase) | 1.26 | 0.98–1.63 | 0.070 |
| Time since HIV diagnosis (per 1 year increase) | 0.93 | 0.85–1.02 | 0.112 |
| Time on ART, (per 1 year increase) | 0.94 | 0.86–1.04 | 0.224 |
|
Antiretroviral regimen before BL - Triple therapy - Dual therapy |
0 1.62 |
0.41–6.30 | 0.484 |
| CDC Stage C | 0.024 | 0.001–4.86 | 0.168 |
| HIV VL ≤30 copies/ml at BL | 0 | ||
| HIV VL ≥30 copies/ml at BL | 1.27 | 0.33–4.92 | 0.731 |
| TCD4 + cells/mm3, median (IQR) at BL | 1.01 | 0.87–1.18 | 0.835 |
| BMI, (per unit increase) | 1.03 | 0.91–1.16 | 0.653 |
| Oral lead in | 0.04 | 0.001-140 | 0.555 |
| PWH with NNRTI resistance-associated mutations (RAMs) at BL | 2.74 | 0.70–10.7 | 0.146 |
|
Comorbidities Cardiovascular disease Endocrinological disorders Hepatology disease Psychiatric disease Neurological disease Pulmonary disease Oncological disease |
0.96 1.04 0.76 0.31 0.36 0.05 0.05 |
0.26-4.00 0.29–3.69 0.19–2.94 0.04–2.44 0.001-38 0.001-inf 0.00-inf |
0.962 0.953 0.693 0.266 0.350 0.774 0.571 |
|
PWH with ≤2 comorbidities, n (%) PWH with ≥2 comorbidities, n(%) |
0 0.34 |
0.88–1.31 | 0.118 |